AC Immune (ACIU) EBITDA (2015 - 2026)
AC Immune (ACIU) posted quarterly EBITDA of -$18.9 million for Q1 2026, up 12.35% year-over-year from -$16.8 million in Q1 2025, and down 4.86% quarter-over-quarter from -$18.0 million in Q4 2025.
AC Immune (ACIU) EBITDA (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported EBITDA for 12 consecutive years, with -$18.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 12.35% year-over-year to -$18.9 million; the TTM figure through Mar 2026 stood at -$80.5 million (down 39.83% YoY), while the FY2025 annual figure was -$83.6 million, down 39.83% from the prior year.
- EBITDA fell to -$18.9 million in Q1 2026 per ACIU's latest filing, from -$18.0 million in the prior quarter.
- Across five years, EBITDA topped out at $8.4 million in Q3 2024 and bottomed at -$23.4 million in Q2 2025.
- Historically, EBITDA has averaged -$17.3 million across 5 years, with a median of -$19.4 million in 2022.
- On a YoY basis, EBITDA climbed as much as 147.92% in 2024 and fell as far as 432.39% in 2024.
- AC Immune's EBITDA stood at -$19.4 million in 2022, then soared by 79.43% to -$4.0 million in 2023, then tumbled by 432.39% to -$21.3 million in 2024, then climbed by 15.26% to -$18.0 million in 2025, then dropped by 4.86% to -$18.9 million in 2026.
- Business Quant data shows ACIU's EBITDA at -$18.9 million in Q1 2026, -$18.0 million in Q4 2025, and -$20.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.51 Mn |
| Mar 31, 2026 | -18.88 Mn |
| Dec 31, 2025 | -18.01 Mn |
| Sep 30, 2025 | -20.21 Mn |
| Jun 30, 2025 | -23.42 Mn |
| Mar 31, 2025 | -21.54 Mn |
| Dec 31, 2024 | -21.25 Mn |
| Sep 30, 2024 | 8.39 Mn |
| Jun 30, 2024 | -23.18 Mn |
| Mar 31, 2024 | -22.99 Mn |
| Dec 31, 2023 | -3.99 Mn |
| Sep 30, 2023 | -17.51 Mn |
| Jun 30, 2023 | -18.96 Mn |
| Mar 31, 2023 | -19.00 Mn |
| Dec 31, 2022 | -19.41 Mn |
| Sep 30, 2022 | -13.94 Mn |
| Jun 30, 2022 | -20.62 Mn |
| Mar 31, 2022 | -20.39 Mn |
| Dec 31, 2021 | -24.71 Mn |
| Sep 30, 2021 | -22.09 Mn |